Immune checkpoint inhibitors (ICIs), as essential components of cancer immunotherapy, exert their antitumor effects by blocking the negative costimulatory signals of T cells, mainly the PD-1/PD-L1 or CTLA-4/CD80/CD86 pathways. This evidence concerns the gene CD274 and cancer.